U.S. Minimal Residual Disease Testing Market Size & Outlook
U.S. minimal residual disease testing market, 2018-2030 (US$M)
Related Markets
U.S. minimal residual disease testing market highlights
- The U.S. minimal residual disease testing market generated a revenue of USD 765.8 million in 2022 and is expected to reach USD 1,635.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 9.9% from 2023 to 2030.
- In terms of segment, flow cytometry was the largest revenue generating technology in 2022.
- Next Generation Sequencing (NGS) is the most lucrative technology segment registering the fastest growth during the forecast period.
Minimal residual disease testing market data book summary
| Market revenue in 2022 | USD 765.8 million |
| Market revenue in 2030 | USD 1,635.4 million |
| Growth rate | 9.9% (CAGR from 2022 to 2030) |
| Largest segment | Flow cytometry |
| Fastest growing segment | Next Generation Sequencing (NGS) |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Polymerase Chain Reaction (PCR), Flow Cytometry, Next Generation Sequencing (NGS) |
| Key market players worldwide | Exact Sciences Corp, Illumina Inc, Natera Inc, Guardant Health Inc, Roche, Foundation Medicine, Qiagen NV, Veracyte Inc, MDxHealth SA, Bio-Techne Corp |
Other key industry trends
- In terms of revenue, U.S. accounted for 40.6% of the global minimal residual disease testing market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. minimal residual disease testing market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 237.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Minimal Residual Disease Testing Market Scope
Minimal Residual Disease Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. minimal residual disease testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to minimal residual disease testing market will help companies and investors design strategic landscapes.
Flow cytometry was the largest segment with a revenue share of 40.05% in 2022. Horizon Databook has segmented the U.S. minimal residual disease testing market based on polymerase chain reaction (pcr), flow cytometry, next generation sequencing (ngs) covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. minimal residual disease testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. minimal residual disease testing market databook
-
Our clientele includes a mix of minimal residual disease testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. minimal residual disease testing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. minimal residual disease testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. minimal residual disease testing market report size, by technology, 2018-2030 (US$M)
U.S. Minimal Residual Disease Testing Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
